KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Payables (2016 - 2026)

Emergent BioSolutions has reported Payables over the past 17 years, most recently at $39.5 million for Q1 2026.

  • For Q1 2026, Payables fell 32.01% year-over-year to $39.5 million; the TTM value through Mar 2026 reached $39.5 million, down 32.01%, while the annual FY2025 figure was $55.6 million, 8.7% down from the prior year.
  • Payables for Q1 2026 was $39.5 million at Emergent BioSolutions, down from $55.6 million in the prior quarter.
  • Over five years, Payables peaked at $1.1 billion in Q1 2023 and troughed at $39.5 million in Q1 2026.
  • A 5-year average of $331.7 million and a median of $137.8 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: skyrocketed 673.87% in 2023 and later plummeted 89.61% in 2025.
  • Year by year, Payables stood at $1.1 billion in 2022, then crashed by 50.42% to $525.9 million in 2023, then plummeted by 88.42% to $60.9 million in 2024, then decreased by 8.7% to $55.6 million in 2025, then decreased by 28.96% to $39.5 million in 2026.
  • Business Quant data shows Payables for EBS at $39.5 million in Q1 2026, $55.6 million in Q4 2025, and $57.4 million in Q3 2025.